Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benzbromarone in Acute Ischemic Cerebrovascular Disease with Hyperuricemia
ChiCTR-IPR-16008313Phase 4Not yet recruiting
- Sponsor
- The Second Affiliated Hospital of Nanjing Medical University
- Start
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of benzbromarone in Ischaemic cerebral disease, transient ischaemic attack (TIA) and hyperuricemia (2 arms), sponsored by The Second Affiliated Hospital of Nanjing Medical University. Primary endpoints: NIHSS score, Barthel index and 1 more. Planned start May 2016; status: not yet recruiting.
02
Drugs
benzbromarone
03
Conditions
Ischaemic cerebral diseasetransient ischaemic attack (TIA)hyperuricemia
Beyond the preview
Go deeper on ChiCTR-IPR-16008313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-16008313.